Sigma Pharmaceuticals (Europe) Limited Filleted accounts for Companies House (small and micro)

Sigma Pharmaceuticals (Europe) Limited Filleted accounts for Companies House (small and micro)


false false false false false false false false false true false false true true false true true No description of principal activity 2017-07-01 Sage Accounts Production Advanced 2018 - FRS 220,000 54,960 1,800 56,760 163,240 165,040 70,167 1,999 619 71,547 71,547 70,167 xbrli:pure xbrli:shares iso4217:GBP 01245628 2017-07-01 2018-06-30 01245628 2018-06-30 01245628 2017-06-30 01245628 2016-07-01 2017-06-30 01245628 2017-06-30 01245628 core:LandBuildings core:OwnedOrFreeholdAssets 2017-07-01 2018-06-30 01245628 bus:RegisteredOffice 2017-07-01 2018-06-30 01245628 bus:LeadAgentIfApplicable 2017-07-01 2018-06-30 01245628 bus:Director1 2017-07-01 2018-06-30 01245628 bus:Director2 2017-07-01 2018-06-30 01245628 bus:Director3 2017-07-01 2018-06-30 01245628 core:LandBuildings 2017-06-30 01245628 core:LandBuildings 2018-06-30 01245628 core:WithinOneYear 2018-06-30 01245628 core:WithinOneYear 2017-06-30 01245628 core:UKTax 2017-07-01 2018-06-30 01245628 core:UKTax 2016-07-01 2017-06-30 01245628 core:ShareCapital 2018-06-30 01245628 core:ShareCapital 2017-06-30 01245628 core:RevaluationReserve 2018-06-30 01245628 core:RevaluationReserve 2017-06-30 01245628 core:RetainedEarningsAccumulatedLosses 2018-06-30 01245628 core:RetainedEarningsAccumulatedLosses 2017-06-30 01245628 core:LandBuildings 2017-07-01 2018-06-30 01245628 core:CostValuation core:Non-currentFinancialInstruments 2017-06-30 01245628 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2018-06-30 01245628 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2018-06-30 01245628 core:CostValuation core:Non-currentFinancialInstruments 2018-06-30 01245628 core:Non-currentFinancialInstruments 2018-06-30 01245628 core:Non-currentFinancialInstruments 2017-06-30 01245628 core:LandBuildings 2017-06-30 01245628 bus:SmallEntities 2017-07-01 2018-06-30 01245628 bus:AuditExemptWithAccountantsReport 2017-07-01 2018-06-30 01245628 bus:FullAccounts 2017-07-01 2018-06-30 01245628 bus:SmallCompaniesRegimeForAccounts 2017-07-01 2018-06-30 01245628 bus:PrivateLimitedCompanyLtd 2017-07-01 2018-06-30
COMPANY REGISTRATION NUMBER: 01245628
Sigma Pharmaceuticals (Europe) Limited
Filleted unaudited financial statements
30 June 2018
Sigma Pharmaceuticals (Europe) Limited
Financial statements
year ended 30 June 2018
Contents
Pages
Officers and professional advisers
1
Chartered accountant's report to the board of directors on the preparation of the unaudited statutory financial statements
2
Statement of financial position
3 to 4
Notes to the financial statements
5 to 8
Sigma Pharmaceuticals (Europe) Limited
Officers and professional advisers
The Board of Directors
Dr B K Shah
Mr M H Shah
Mr K H Shah
Registered Office
273-287 Regent Street
London
W1B 2HA
Accountants
King & King
Chartered accountant
Roxburghe House
273-287 Regent Street
London
W1B 2HA
Bankers
National Westminster Bank Plc
275-277 High Street
Hounslow
Middlesex
UAE
TW3 1ZA
Sigma Pharmaceuticals (Europe) Limited
Chartered accountant's report to the board of directors on the preparation of the unaudited statutory financial statements of Sigma Pharmaceuticals (Europe) Limited
year ended 30 June 2018
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Sigma Pharmaceuticals (Europe) Limited for the year ended 30 June 2018, which comprise the statement of financial position and the related notes from the company's accounting records and from information and explanations you have given us. As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/membership/regulations-standards-and-guidance. This report is made solely to the Board of Directors of Sigma Pharmaceuticals (Europe) Limited, as a body, in accordance with the terms of our engagement letter dated 29 October 2018. Our work has been undertaken solely to prepare for your approval the financial statements of Sigma Pharmaceuticals (Europe) Limited and state those matters that we have agreed to state to you, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF as detailed at www.icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Sigma Pharmaceuticals (Europe) Limited and its Board of Directors, as a body, for our work or for this report.
It is your duty to ensure that Sigma Pharmaceuticals (Europe) Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Sigma Pharmaceuticals (Europe) Limited. You consider that Sigma Pharmaceuticals (Europe) Limited is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the financial statements of Sigma Pharmaceuticals (Europe) Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
King & King Chartered accountant
Roxburghe House 273-287 Regent Street London W1B 2HA
25 March 2019
Sigma Pharmaceuticals (Europe) Limited
Statement of financial position
30 June 2018
2018
2017
Note
£
£
Fixed assets
Tangible assets
5
163,240
165,040
Investments
6
71,547
70,167
----------
----------
234,787
235,207
Current assets
Debtors
7
1,061
6,873
Cash at bank and in hand
223,097
202,857
----------
----------
224,158
209,730
Creditors: amounts falling due within one year
8
6,548
6,245
----------
----------
Net current assets
217,610
203,485
----------
----------
Total assets less current liabilities
452,397
438,692
----------
----------
Net assets
452,397
438,692
----------
----------
Sigma Pharmaceuticals (Europe) Limited
Statement of financial position (continued)
30 June 2018
2018
2017
Note
£
£
Capital and reserves
Called up share capital
2,100
2,100
Revaluation reserve
9
155,431
155,431
Profit and loss account
9
294,866
281,161
----------
----------
Shareholders funds
452,397
438,692
----------
----------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 30 June 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 25 March 2019 , and are signed on behalf of the board by:
Dr B K Shah
Director
Company registration number: 01245628
Sigma Pharmaceuticals (Europe) Limited
Notes to the financial statements
year ended 30 June 2018
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 273-287 Regent Street, London, W1B 2HA.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The financial statements have been prepared on a going concern basis. The company should be able to manage its business risk successfully. After making appropriate enquiries, the directors have a reasonable expectation that the company has adequate resources available to it to continue its operational business for the foreseeable future and have therefore adopted the going concern basis in preparing the financial statements.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that effect the amounts received. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Freehold property
-
2% straight line
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.
4. Tax on profit
Major components of tax expense
2018
2017
£
£
Current tax:
UK current tax expense
3,637
2,995
-------
-------
Tax on profit
3,637
2,995
-------
-------
5. Tangible assets
Land and buildings
£
Cost
At 1 July 2017 and 30 June 2018
220,000
----------
Depreciation
At 1 July 2017
54,960
Charge for the year
1,800
----------
At 30 June 2018
56,760
----------
Carrying amount
At 30 June 2018
163,240
----------
At 30 June 2017
165,040
----------
Tangible assets held at valuation
The freehold property was last revalued by the directors on 30 June 2008. The next valuation will be carried out in the year ended 30 June 2015. The directors' are of the opinion that the valuation is fair and not materially different from market value as at 30 June 2018.
6. Investments
Other investments other than loans
£
Cost
At 1 July 2017
70,167
Additions
1,999
Revaluations
( 619)
---------
At 30 June 2018
71,547
---------
Impairment
At 1 July 2017 and 30 June 2018
---------
Carrying amount
At 30 June 2018
71,547
---------
At 30 June 2017
70,167
---------
7. Debtors
2018
2017
£
£
Trade debtors
495
6,168
Other debtors
566
705
-------
-------
1,061
6,873
-------
-------
8. Creditors: amounts falling due within one year
2018
2017
£
£
Corporation tax
3,636
2,996
Other creditors
2,912
3,249
-------
-------
6,548
6,245
-------
-------
9. Reserves
Revaluation reserve - This reserve records the value of asset revaluations and fair value movements on assets recognised in other comprehensive income. Profit and loss account - This reserve records retained earnings and accumulated losses.
10. Directors' advances, credits and guarantees
No directors received any advances or credits from the company.
11. Related party transactions
No transactions were undertaken with related parties as would be required to be disclosed.
12. Controlling party
The company was under the equal control of its three directors.